MEI Pharma's EPS (Basic) for the
three
months ended in Dec. 2023 was $-1.66.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $2.97.
MEI Pharma's EPS without NRI for the
three
months ended in Dec. 2023 was $-1.66.
Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $2.97.
During the past 3 years, the average EPS without NRIGrowth Rate was 2.30% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 16.60% per year.
During the past 13 years, MEI Pharma's highest 3-Year average EPS without NRI Growth Rate was 44.50% per year. The lowest was -29.40% per year. And the median was 13.95% per year.
MEI Pharma Earnings per Share (Diluted) Historical Data
The historical data trend for MEI Pharma's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of MEI Pharma's Earnings per Share (Diluted)
For the Biotechnology subindustry, MEI Pharma's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MEI Pharma's PE Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MEI Pharma's PE Ratio distribution charts can be found below:
* The bar in red indicates where MEI Pharma's PE Ratio falls into.
MEI Pharma Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
MEI Pharma's Earnings Per Share (Diluted) for the fiscal year that ended in Jun. 2023 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.97
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
MEI Pharma (NAS:MEIP) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
MEI Pharma Earnings per Share (Diluted) Related Terms
Thank you for viewing the detailed overview of MEI Pharma's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MEIP has been successfully added to your 